MedTrace Logo

A Study of HLX42 in Advanced/Metastatic Solid Tumors

NCT06210815 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2025-09-22

No results posted yet for this study

Summary

This study is an open-label first-in-human phase I clinical study to evaluate the safety and tolerability of HLX42.

Conditions

  • Solid Tumor and NSCLC

Interventions

DRUG

HLX42

HLX42 is an anti-EGFR monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.

Sponsors & Collaborators

Principal Investigators

  • Yilong Wu, Dr. · Guangdong Provincial People's Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-14
Primary Completion
2026-09-02
Completion
2027-06-14
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06210815 on ClinicalTrials.gov